Oppenheimer & CO Inc Lexicon Pharmaceuticals, Inc. Transaction History
Oppenheimer & CO Inc
- $7.23 Billion
- Q2 2025
A detailed history of Oppenheimer & CO Inc transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 23,500 shares of LXRX stock, worth $33,605. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,500
Previous 20,100
16.92%
Holding current value
$33,605
Previous $9,000
144.44%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding LXRX
# of Institutions
129Shares Held
226MCall Options Held
431KPut Options Held
138K-
Artal Group S.A. Luxembourg, N4136MShares$195 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$55.7 Million1.9% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$14.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.85MShares$12.7 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY4.58MShares$6.54 Million0.03% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $270M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...